Compare
Vera Therapeutics, Inc. vs Aurinia Pharmaceuticals Inc. vs Arvinas, Inc. vs Cryoport, Inc.
| Latest fiscal year | Vera Therapeutics, Inc. VERA | Aurinia Pharmaceuticals Inc. AUPHRevenue covers only part of its income (partial revenue) | Arvinas, Inc. ARVN | Cryoport, Inc. CYRX |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | n/a | $262.60M | $176.18M |
| Revenue growth (YoY) | n/a | n/a | -0.3% | +12.4% |
| Gross margin | n/a | n/a | n/a | 47.1% |
| Operating margin | n/a | n/a | -45.1% | -20.9% |
| Net margin | n/a | n/a | -30.8% | 44.4% |
| Net income | -$299.62M | $287.20M | -$80.80M | $78.30M |
| EPS (Diluted) | -$4.66 | $2.07 | -$1.14 | $1.40 |
| Operating cash flow | -$241.10M | $135.66M | -$273.80M | -$8.58M |
| Free cash flow | -$241.73M | n/a | -$275.70M | -$25.02M |
| Cash & equivalents | $354.73M | $80.16M | $142.90M | $250.49M |
| Total assets | $734.73M | $751.59M | $717.90M | $764.99M |
| Total liabilities | $130.21M | $170.26M | $284.00M | $262.35M |
| Shareholders' equity | $604.52M | $581.33M | $433.90M | $502.64M |
| Return on year-end equity | -49.6% | 49.4% | -18.6% | 15.6% |
| Shares outstanding | n/a | 132.32M | 63.50M | 49.85M |
Revenue, most recent five fiscal years
| Fiscal year | Vera Therapeutics, Inc. | Aurinia Pharmaceuticals Inc. | Arvinas, Inc. | Cryoport, Inc. |
|---|---|---|---|---|
| Latest | n/a | n/a | $262.60M Ended 2025-12-31 | $176.18M Ended 2025-12-31 |
| 1 year earlier | n/a | n/a | $263.40M Ended 2024-12-31 | $156.77M Ended 2024-12-31 |
| 2 years earlier | n/a | n/a | $78.50M Ended 2023-12-31 | $168.66M Ended 2023-12-31 |
| 3 years earlier | n/a | n/a | $131.40M Ended 2022-12-31 | $237.28M Ended 2022-12-31 |
| 4 years earlier | n/a | n/a | $53.60M Ended 2021-12-31 | $222.61M Ended 2021-12-31 |